Covered recipient · General Payments record
ARVIND CHAUDHRY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$7,009.94
211 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,697.95 | 206 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,810.00 | 2 |
| Consulting Fee | $1,011.00 | 1 |
| Travel and Lodging | $426.00 | 1 |
| Education | $64.99 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ARVIND CHAUDHRY
NPI 1750336236 · CMS profile ID 34432
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SPOKANE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750336236?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750336236?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750336236?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1750336236?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
211 matching records · $7,009.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 211.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $17.65 | 10/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741369307 | CMS |
| Astellas Pharma US Inc | $19.09 | 10/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718308567 | CMS |
| AbbVie Inc. | $18.09 | 09/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721726485 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.85 | 09/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720976917 | CMS |
| Celgene Corporation | $23.86 | 09/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727856109 | CMS |
| Blueprint Medicines Corporation | $20.67 | 09/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750714883 | CMS |
| Amgen Inc. | $24.08 | 09/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740919521 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727856065 | CMS |
| Lilly USA, LLC | $17.55 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728358317 | CMS |
| PFIZER INC. | $12.49 | 09/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743340737 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $17.75 | 09/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725675095 | CMS |
| ARRAY BIOPHARMA INC | $17.19 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743766261 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.69 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744128299 | CMS |
| PFIZER INC. | $25.00 | 09/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743373941 | CMS |
| PFIZER INC. | $13.15 | 09/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743372958 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.67 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727856059 | CMS |
| Rigel Pharmaceuticals, Inc. | $32.50 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752091529 | CMS |
| Rigel Pharmaceuticals, Inc. | $19.09 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752091555 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.76 | 08/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736006215 | CMS |
| Eisai Inc. | $22.33 | 08/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751226025 | CMS |
| Amgen Inc. | $17.27 | 08/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740919515 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,350.00 | 08/27/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725667335 | CMS |
| Eisai Inc. | $21.50 | 08/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751223807 | CMS |
| Acceleron Pharma, Inc. | $17.19 | 08/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 712262401 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.69 | 08/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735879509 | CMS |
| Lilly USA, LLC | $17.40 | 08/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728365199 | CMS |
| Amgen Inc. | $1.48 | 08/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740919497 | CMS |
| EMD Serono, Inc. | $13.78 | 08/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751284255 | CMS |
| Dova Pharmaceuticals | $18.96 | 08/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752353465 | CMS |
| Seagen Inc. | $17.31 | 08/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732448659 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.78 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727856057 | CMS |
| BeiGene USA, Inc. | $13.27 | 08/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752947703 | CMS |
| Amgen Inc. | $12.74 | 08/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740919501 | CMS |
| Sirtex Medical Inc | $16.73 | 08/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 734604693 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.55 | 08/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736399273 | CMS |
| BTG INTERNATIONAL, INC. | $16.50 | 08/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 717716725 | CMS |
| Merck Sharp & Dohme Corporation | $23.09 | 08/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747721925 | CMS |
| Sun Pharmaceutical Industries Inc. | $19.56 | 08/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728282861 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.82 | 07/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721008847 | CMS |
| Celgene Corporation | $18.07 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727856107 | CMS |
| PFIZER INC. | $21.29 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743242863 | CMS |
| SANOFI-AVENTIS U.S. LLC | $14.96 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744128257 | CMS |
| Kite Pharma, Inc. | $15.14 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731507861 | CMS |
| Foundation Medicine, Inc. | $14.79 | 07/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 714555437 | CMS |
| Eisai Inc. | $19.91 | 07/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751432921 | CMS |
| Eisai Inc. | $20.13 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751212667 | CMS |
| Genentech USA, Inc. | $13.16 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742985913 | CMS |
| Genentech USA, Inc. | $16.45 | 07/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742985959 | CMS |
| Lexicon Pharmaceuticals, Inc. | $16.22 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751838691 | CMS |
| GENZYME CORPORATION | $23.52 | 07/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744128253 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $120.37 | 3 |
| PY2025 | Principal investigator | $983,880.56 | 173 |
| PY2024 | Principal investigator | $999,041.50 | 152 |
| PY2023 | Principal investigator | $2,006,085.88 | 155 |
| PY2022 | Principal investigator | $1,788,082.83 | 163 |
| PY2021 | Principal investigator | $2,822,985.04 | 252 |
| PY2020 | Recipient | $10,000.00 | 1 |
| PY2020 | Principal investigator | $2,128,155.63 | 311 |
| PY2019 | Recipient | $9,301.70 | 4 |
| PY2019 | Principal investigator | $657,825.25 | 132 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
176 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,529.76 | 12/31/2025 | Non-covered Recipient Entity Medical Oncology Associates Summit Cancer Centers | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232925793 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,253.54 | 12/31/2025 | Non-covered Recipient Entity Medical Oncology Associates Summit Cancer Centers | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232926707 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $25,076.00 | 12/30/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190329689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,393.00 | 12/22/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175399559 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,090.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185537567 |
| Principal investigator 1 | ABBVIE INC. | $1,718.55 | 12/04/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202528410 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $1,712.40 | 11/26/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516804 |
| Principal investigator 1 | PFIZER INC. | $1,537.28 | 11/24/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228813733 |
| Principal investigator 1 | PFIZER INC. | $6,145.00 | 11/17/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228813751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,860.37 | 11/14/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175399575 |
| Principal investigator 1 | ABBVIE INC. | $19,227.50 | 11/05/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202523143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.75 | 11/03/2025 | Non-covered Recipient Entity Medical Oncology Associates P S Spokane | DS1062-328 | No dispute reported | 06/30/2026 | 1223372102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $94.00 | 11/03/2025 | Non-covered Recipient Entity Medical Oncology Associates P S Spokane | DS1062-328 | No dispute reported | 06/30/2026 | 1223372104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $376.00 | 11/03/2025 | Non-covered Recipient Entity Medical Oncology Associates P S Spokane | DS1062-328 | No dispute reported | 06/30/2026 | 1223372106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,393.00 | 11/03/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175399548 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $10,661.10 | 10/31/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516593 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $2,825.00 | 10/31/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516810 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 10/16/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202517379 |
| Principal investigator 1 | ABBVIE INC. | $4,094.87 | 10/16/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202517381 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 10/16/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202517383 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/16/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202517385 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 10/16/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202517397 |
| Principal investigator 1 | ABBVIE INC. | $2,250.00 | 10/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202516439 |
| Principal investigator 1 | Exelixis Inc. | $2,079.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381580 |
| Principal investigator 1 | Exelixis Inc. | $1,049.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381582 |
| Principal investigator 1 | Exelixis Inc. | $396.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381584 |
| Principal investigator 1 | Exelixis Inc. | $1,980.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381586 |
| Principal investigator 1 | Exelixis Inc. | $594.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381588 |
| Principal investigator 1 | Exelixis Inc. | $3,465.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381590 |
| Principal investigator 1 | Exelixis Inc. | $495.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381592 |
| Principal investigator 1 | Exelixis Inc. | $2,640.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381594 |
| Principal investigator 1 | Exelixis Inc. | $132.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381596 |
| Principal investigator 1 | Exelixis Inc. | $6,501.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381598 |
| Principal investigator 1 | Exelixis Inc. | $792.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381600 |
| Principal investigator 1 | Exelixis Inc. | $2,059.00 | 10/06/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222381602 |
| Principal investigator 1 | Organon Llc | $20,508.00 | 09/24/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | 1026-003 | No dispute reported | 06/30/2026 | 1173042146 |
| Principal investigator 1 | Organon Llc | $2,600.00 | 09/24/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | 1026-003 | No dispute reported | 06/30/2026 | 1173042412 |
| Principal investigator 1 | Organon Llc | $30,807.00 | 09/19/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | 1026-003 | No dispute reported | 06/30/2026 | 1173042410 |
| Principal investigator 1 | Exelixis Inc. | $4,011.00 | 09/08/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222381606 |
| Principal investigator 1 | Exelixis Inc. | $170.00 | 09/08/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222381608 |
| Principal investigator 1 | Exelixis Inc. | $592.00 | 09/08/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222381610 |
| Principal investigator 1 | Organon Llc | $6,010.80 | 09/08/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | 2140-006 | No dispute reported | 06/30/2026 | 1173042528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,131.00 | 09/01/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399593 |
| Principal investigator 1 | Amgen Inc. | $3,550.00 | 08/22/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246644179 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,374.67 | 08/13/2025 | Non-covered Recipient Entity Medical Oncology Associates, Ps | A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1235995917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,168.00 | 08/11/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399568 |
| Principal investigator 1 | AstraZeneca UK Limited | $27,553.00 | 07/31/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression | No dispute reported | 06/30/2026 | 1185537565 |
| Principal investigator 1 | Exelixis Inc. | $6,769.60 | 07/23/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,750.00 | 07/22/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399598 |
| Principal investigator 1 | Amgen Inc. | $83,008.55 | 07/18/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | No dispute reported | 06/30/2026 | 1246644188 |
| Principal investigator 1 | Exelixis Inc. | $1,793.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381548 |
| Principal investigator 1 | Exelixis Inc. | $9,093.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381550 |
| Principal investigator 1 | Exelixis Inc. | $1,365.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381552 |
| Principal investigator 1 | Exelixis Inc. | $479.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381554 |
| Principal investigator 1 | Exelixis Inc. | $550.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381556 |
| Principal investigator 1 | Exelixis Inc. | $7,218.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381558 |
| Principal investigator 1 | Exelixis Inc. | $1,917.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381560 |
| Principal investigator 1 | Exelixis Inc. | $36,654.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381562 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381564 |
| Principal investigator 1 | Exelixis Inc. | $44.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381568 |
| Principal investigator 1 | Exelixis Inc. | $655.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381570 |
| Principal investigator 1 | Exelixis Inc. | $1,500.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381572 |
| Principal investigator 1 | Exelixis Inc. | $1,519.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381574 |
| Principal investigator 1 | Exelixis Inc. | $4,111.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381576 |
| Principal investigator 1 | Exelixis Inc. | $2,500.00 | 07/09/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381578 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 06/26/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190330125 |
| Principal investigator 1 | Gilead Sciences, Inc. | $29,249.00 | 06/13/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES P S | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physican's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) | No dispute reported | 06/30/2026 | 1229213455 |
| Principal investigator 1 | PFIZER INC. | $1,537.28 | 06/02/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228844031 |
| Recipient | ABBVIE INC. | $25.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202397637 |
| Recipient | ABBVIE INC. | $47.37 | 05/30/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202397640 |
| Recipient | ABBVIE INC. | $48.00 | 05/30/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202397644 |
| Principal investigator 1 | PFIZER INC. | $5,020.00 | 05/19/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228844192 |
| Principal investigator 1 | ABBVIE INC. | $688.77 | 05/15/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202485235 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $71,000.00 | 05/11/2025 | Non-covered Recipient Entity Medical Oncology Associates | A Phase I, Open-label, Multicenter Study of ZL 1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Malignancies | No dispute reported | 06/30/2026 | 1232935505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,834.00 | 05/08/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,910.00 | 04/08/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,985.00 | 04/08/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,200.00 | 03/28/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399554 |
| Principal investigator 1 | Acerta Pharma LLC | $10,726.62 | 03/27/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation | No dispute reported | 06/30/2026 | 1185537563 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,453.76 | 03/20/2025 | Non-covered Recipient Entity Summit Cancer Centers | A Phase 1b,2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGF R Serine,Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232932117 |
| Principal investigator 1 | Acerta Pharma LLC | $8,134.01 | 03/18/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia | No dispute reported | 06/30/2026 | 1185537561 |
| Principal investigator 1 | PFIZER INC. | $7,240.00 | 03/10/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER | No dispute reported | 06/30/2026 | 1228846157 |
| Principal investigator 1 | AstraZeneca UK Limited | $37,211.62 | 02/28/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1185537559 |
| Principal investigator 1 | Exelixis Inc. | $360.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381408 |
| Principal investigator 1 | Exelixis Inc. | $170.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381410 |
| Principal investigator 1 | Exelixis Inc. | $214.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381412 |
| Principal investigator 1 | Exelixis Inc. | $148.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381418 |
| Principal investigator 1 | Exelixis Inc. | $61.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381420 |
| Principal investigator 1 | Exelixis Inc. | $176.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381422 |
| Principal investigator 1 | Exelixis Inc. | $124.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381424 |
| Principal investigator 1 | Exelixis Inc. | $122.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381428 |
| Principal investigator 1 | Exelixis Inc. | $4,111.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381430 |
| Principal investigator 1 | Exelixis Inc. | $61.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381432 |
| Principal investigator 1 | Exelixis Inc. | $73.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381434 |
| Principal investigator 1 | Exelixis Inc. | $130.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381438 |
| Principal investigator 1 | Exelixis Inc. | $81.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381440 |
| Principal investigator 1 | Exelixis Inc. | $97.01 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381442 |
| Principal investigator 1 | Exelixis Inc. | $122.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381444 |
| Principal investigator 1 | Exelixis Inc. | $64.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381448 |
| Principal investigator 1 | Exelixis Inc. | $410.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381450 |
| Principal investigator 1 | Exelixis Inc. | $54.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381452 |
| Principal investigator 1 | Exelixis Inc. | $172.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381454 |
| Principal investigator 1 | Exelixis Inc. | $116.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381456 |
| Principal investigator 1 | Exelixis Inc. | $162.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381458 |
| Principal investigator 1 | Exelixis Inc. | $136.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381460 |
| Principal investigator 1 | Exelixis Inc. | $63.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381462 |
| Principal investigator 1 | Exelixis Inc. | $74.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381464 |
| Principal investigator 1 | Exelixis Inc. | $5,817.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381466 |
| Principal investigator 1 | Exelixis Inc. | $205.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381468 |
| Principal investigator 1 | Exelixis Inc. | $88.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381470 |
| Principal investigator 1 | Exelixis Inc. | $65.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381472 |
| Principal investigator 1 | Exelixis Inc. | $2,406.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381474 |
| Principal investigator 1 | Exelixis Inc. | $406.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381476 |
| Principal investigator 1 | Exelixis Inc. | $221.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381478 |
| Principal investigator 1 | Exelixis Inc. | $122.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381480 |
| Principal investigator 1 | Exelixis Inc. | $406.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381482 |
| Principal investigator 1 | Exelixis Inc. | $62.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381484 |
| Principal investigator 1 | Exelixis Inc. | $128.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381486 |
| Principal investigator 1 | Exelixis Inc. | $122.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381488 |
| Principal investigator 1 | Exelixis Inc. | $88.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381490 |
| Principal investigator 1 | Exelixis Inc. | $136.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381492 |
| Principal investigator 1 | Exelixis Inc. | $172.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381494 |
| Principal investigator 1 | Exelixis Inc. | $221.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381496 |
| Principal investigator 1 | Exelixis Inc. | $371.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381498 |
| Principal investigator 1 | Exelixis Inc. | $254.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381500 |
| Principal investigator 1 | Exelixis Inc. | $190.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381502 |
| Principal investigator 1 | Exelixis Inc. | $3,031.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381504 |
| Principal investigator 1 | Exelixis Inc. | $95.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381506 |
| Principal investigator 1 | Exelixis Inc. | $86.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381508 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381510 |
| Principal investigator 1 | Exelixis Inc. | $256.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381512 |
| Principal investigator 1 | Exelixis Inc. | $68.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381514 |
| Principal investigator 1 | Exelixis Inc. | $1,793.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381518 |
| Principal investigator 1 | Exelixis Inc. | $108.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381520 |
| Principal investigator 1 | Exelixis Inc. | $122.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381522 |
| Principal investigator 1 | Exelixis Inc. | $80.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381524 |
| Principal investigator 1 | Exelixis Inc. | $80.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381526 |
| Principal investigator 1 | Exelixis Inc. | $63.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381528 |
| Principal investigator 1 | Exelixis Inc. | $131.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381530 |
| Principal investigator 1 | Exelixis Inc. | $4,111.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381532 |
| Principal investigator 1 | Exelixis Inc. | $61.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381536 |
| Principal investigator 1 | Exelixis Inc. | $146.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381538 |
| Principal investigator 1 | Exelixis Inc. | $176.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381540 |
| Principal investigator 1 | Exelixis Inc. | $61.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381542 |
| Principal investigator 1 | Exelixis Inc. | $2,730.00 | 02/21/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381546 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,568.00 | 02/20/2025 | Non-covered Recipient Entity Summit Cancer Centers North Spokane | Brightline-4 | No dispute reported | 06/30/2026 | 1220817402 |
| Principal investigator 1 | Acerta Pharma LLC | $27,927.69 | 02/18/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185537557 |
| Principal investigator 1 | Exelixis Inc. | $86.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381414 |
| Principal investigator 1 | Exelixis Inc. | $820.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381416 |
| Principal investigator 1 | Exelixis Inc. | $54.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381426 |
| Principal investigator 1 | Exelixis Inc. | $81.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381436 |
| Principal investigator 1 | Exelixis Inc. | $240.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381446 |
| Principal investigator 1 | Exelixis Inc. | $32.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381516 |
| Principal investigator 1 | Exelixis Inc. | $186.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381534 |
| Principal investigator 1 | Exelixis Inc. | $219.00 | 02/12/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222381544 |
| Principal investigator 1 | Amgen Inc. | $1,227.00 | 01/29/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer | No dispute reported | 06/30/2026 | 1246644191 |
| Principal investigator 1 | Exelixis Inc. | $33,530.00 | 01/24/2025 | Non-covered Recipient Entity Medical Oncology Associates PS | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222381604 |
| Principal investigator 1 | Eli Lilly and Company | $29,758.06 | 01/22/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES PS | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187886518 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,500.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910481 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,500.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910483 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,600.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910485 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,060.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910487 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $750.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910489 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,000.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910491 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,100.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910493 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $755.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910495 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $998.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910497 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $700.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910499 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,700.00 | 01/09/2025 | Non-covered Recipient Entity MEDICAL ONCOLOGY ASSOCIATES, P.S. | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199910501 |
| Principal investigator 1 | BeiGene, Ltd. | $1,500.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320010 |
| Principal investigator 1 | BeiGene, Ltd. | $2,275.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324174 |
| Principal investigator 1 | BeiGene, Ltd. | $750.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324620 |
| Principal investigator 1 | BeiGene, Ltd. | $2,000.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324632 |
| Principal investigator 1 | BeiGene, Ltd. | $680.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324654 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324668 |
| Principal investigator 1 | BeiGene, Ltd. | $5,592.00 | 01/06/2025 | Non-covered Recipient Entity Medical Oncology Associates, PS | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324680 |